Literature DB >> 16487241

Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease.

K Matsubara1, T Fukaya, K Miwa, N Shibayama, H Nigami, H Harigaya, H Nozaki, T Hirata, K Baba, T Suzuki, A Ishiguro.   

Abstract

To serologically determine the association of microbial superantigens and the pathogenesis of Kawasaki disease (KD), we conducted a case-control study. Serum IgG and IgM antibodies against staphylococcal enterotoxin A (SEA), SEB, SEC, toxic shock syndrome toxin-1 (TSST-1), and streptococcal pyrogenic exotoxin A (SPEA) were measured by an enzyme-linked immunosorbent assay in 293 serum samples from 65 KD patients on clinical days 1-28 and 120 control samples. The administration of immunoglobulin products, which contain high concentrations of IgG antibodies against all the superantigens, directly elevated antitoxin IgG antibodies in KD patients. In contrast, antitoxin IgM antibodies were not detected in immunoglobulin products. Actually, we found a significant elevation of IgM antibodies against SEA in KD patients in the first (median titre: 0.020, P < 0.01 versus control), second (0.024, P < 0.001), third (0.030, P < 0.001) and fourth (0.038, P < 0.001) weeks, compared to the controls (0.015). Significant differences of IgM antibodies were also true for SEB, TSST-1, and SPEA throughout the first to fourth weeks, and for SEC throughout the second to fourth weeks. The prevalence of KD patients having high IgM titres (> mean + 2SD of control values) to the 5 superantigens was increased with the clinical weeks, and reached 29-43% of KD subjects at the fourth week. This is the first study that describes kinetics of IgM antibodies against superantigens and clarifies the serological significance throughout the clinical course of KD. Our results suggest that multiple superantigens involve in the pathogenesis of KD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487241      PMCID: PMC1809617          DOI: 10.1111/j.1365-2249.2006.03015.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Sensitive enzyme-linked immunosorbent assays for the detection of bacterial superantigens and antibodies against them in human plasma.

Authors:  K Miwa; M Fukuyama; R Sakai; S Shimizu; N Ida; M Endo; H Igarashi
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

Review 2.  Determination of reference intervals in the clinical laboratory using the proposed guideline National Committee for Clinical Laboratory Standards C28-P.

Authors:  E A Sasse
Journal:  Arch Pathol Lab Med       Date:  1992-07       Impact factor: 5.534

3.  Human T cell-dependent B cell differentiation induced by staphylococcal superantigens.

Authors:  W Stohl; J E Elliott; P S Linsley
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

4.  Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].

Authors:  S Takei; Y K Arora; S M Walker
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

5.  In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class II.

Authors:  W Stohl; D Xu; S Zang; K S Kim; L Li; J A Hanson; S A Stohlman; C S David; C O Jacob
Journal:  Int Immunol       Date:  2001-10       Impact factor: 4.823

6.  Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome.

Authors:  Yuichi Nomura; Masao Yoshinaga; Kiminori Masuda; Syuji Takei; Koichiro Miyata
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

7.  Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease.

Authors:  Takeshi Yoshioka; Takaji Matsutani; Tomoko Toyosaki-Maeda; Hiroyuki Suzuki; Sigeru Uemura; Ryuji Suzuki; Michio Koike; Yorio Hinuma
Journal:  Pediatr Res       Date:  2003-03       Impact factor: 3.756

8.  Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease.

Authors:  Donald Y M Leung; H Cody Meissner; Stanford T Shulman; Wilbert H Mason; Michael A Gerber; Mary P Glode; Barry L Myones; J Gary Wheeler; Robin Ruthazer; Patrick M Schlievert
Journal:  J Pediatr       Date:  2002-06       Impact factor: 4.406

9.  Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease.

Authors:  J Abe; B L Kotzin; K Jujo; M E Melish; M P Glode; T Kohsaka; D Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.

Authors:  D Y Leung; H C Meissner; D R Fulton; D L Murray; B L Kotzin; P M Schlievert
Journal:  Lancet       Date:  1993-12-04       Impact factor: 79.321

View more
  22 in total

1.  Incomplete Kawasaki disease associated with complicated Streptococcus pyogenes pneumonia: A case report.

Authors:  Timothy Ronan Leahy; Eyal Cohen; Upton D Allen
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

2.  Lipid-derived free radical production in superantigen-induced interstitial pneumonia.

Authors:  Hisako Miyakawa; Ronald P Mason; Jinjie Jiang; Maria B Kadiiska
Journal:  Free Radic Biol Med       Date:  2009-04-17       Impact factor: 7.376

Review 3.  Sex Differences in Pediatric Rheumatology.

Authors:  Marco Cattalini; Martina Soliani; Maria Costanza Caparello; Rolando Cimaz
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

Review 4.  Kawasaki disease: etiopathogenesis and novel treatment strategies.

Authors:  Shreya Agarwal; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2016-09-13       Impact factor: 4.473

5.  Hepatic dysfunction secondary to Kawasaki disease: characteristics, etiology and predictive role in coronary artery abnormalities.

Authors:  Goshgar Mammadov; Hui Hui Liu; Wei Xia Chen; Guo Zhen Fan; Rui Xue Li; Fei Fei Liu; Sama Samadli; Jing Jing Wang; Yang Fang Wu; Huang Huang Luo; Dong Dong Zhang; Wei Wei; Peng Hu
Journal:  Clin Exp Med       Date:  2019-11-16       Impact factor: 3.984

6.  T cell activation profiles in Kawasaki syndrome.

Authors:  P A Brogan; V Shah; L A Clarke; M J Dillon; N Klein
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

Review 7.  Epigenetics in Kawasaki Disease.

Authors:  Kaushal Sharma; Pandiarajan Vignesh; Priyanka Srivastava; Jyoti Sharma; Himanshi Chaudhary; Sanjib Mondal; Anupriya Kaur; Harvinder Kaur; Surjit Singh
Journal:  Front Pediatr       Date:  2021-06-25       Impact factor: 3.418

Review 8.  Progress in treatment of ANCA-associated vasculitis.

Authors:  Rona M Smith; Rachel B Jones; David R W Jayne
Journal:  Arthritis Res Ther       Date:  2012-04-30       Impact factor: 5.156

Review 9.  Medium-size-vessel vasculitis.

Authors:  Michael J Dillon; Despina Eleftheriou; Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2009-11-28       Impact factor: 3.714

10.  Clinical characteristics of Kawasaki disease and concurrent pathogens during isolation in COVID-19 pandemic.

Authors:  Yue-Yue Ding; Yan Ren; Jie Qin; Guang-Hui Qian; Yun-Jia Tang; Ye Chen; Xuan Li; Lei Xu; Chun-Hong Qiao; Ling Sun; Hai-Tao Lv
Journal:  World J Pediatr       Date:  2021-06-23       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.